Search clinical trials for: Placebo (for Eltrombopag)

Total 69309 results

B. Höchsmann

Recruiting

Efficacy and Safety of Eltrombopag + CSA in Patients With Moderate Aplastic Anemia (EMAA) (EMAA)

Anemia, Aplastic

Germany
GlaxoSmithKline

Completed

Meta-analysis - Eltrombopag

Thrombocytopaenia
GlaxoSmithKline

Completed

RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag (RAISE)

Purpura, Thrombocytopaenic, Idiopathic

United States, Taiwan, Italy, Poland, Peru, Canada, Denmark, Germany, Slovakia, Spain, United Kingdom, New Zealand, China, Greece, Hong Kong, Russian Federation, Austria, Netherlands, Czech Republic, France, India, Ukraine, Tunisia, F... and more
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence

Myelodysplastic Syndromes

Japan
GlaxoSmithKline

Completed

Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP) (PETIT)

Purpura, Thrombocytopaenic, Idiopathic

United States, France, Netherlands, Spain, United Kingdom, Canada
GlaxoSmithKline

Completed

Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. (PETIT2)

Idiopathic Thrombocytopenic Purpura

Thailand, Israel, Poland, Russian Federation, Spain, Germany, United Kingdom, Taiwan, Hong Kong, Czech Republic, Italy, United States, Argentina
M.D. Anderson Cancer Center
Novartis Pharmaceuticals

Completed

Eltrombopag for Post Transplant Thrombocytopenia

Thrombocytopenia

United States
Chang Gung Memorial Hospital
Novartis

Unknown

A Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced Thrombocytopenia

Solid Tumor

Taiwan
Associazione Qol-one

Active, not recruiting

Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes | Thrombocytopenia

France, Germany, Italy, Slovenia
Novartis Pharmaceuticals

Completed

Eltrombopag Phase III Study In Chinese Chronic ITP Patients

Purpura, Thrombocytopenic, Idiopathic and Hepatitis C

China
GlaxoSmithKline

Completed

Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)

Myelodysplastic Syndrome

Puerto Rico, United States, Taiwan, Germany, Denmark, Hong Kong, Korea, Republic of, France, United Kingdom, Italy, Brazil
GlaxoSmithKline

Completed

Indirect Comparison Between Eltrombopag & Romiplostim

Thrombocytopaenia
Novartis Pharmaceuticals

Completed

A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (ASPIRE)

Thrombocytopaenia

United States, Belgium, Canada, Hong Kong, Argentina, Brazil, Czechia, Germany, Greece, Israel, Netherlands, Spain, Thailand, Hungary, Ireland, Italy, Mexico, Taiwan, Korea, Republic of, Poland, Russian Federation, Puerto Rico
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.

Chemotherapy-Induced Thrombocytopenia
Novartis Pharmaceuticals

Completed

A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Purpura, Thrombocytopenic, Idiopathic

Russian Federation
GlaxoSmithKline

Terminated

Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures (ELEVATE)

Liver Diseases | HIV Infection | Thrombocytopenia | Hepatitis C Virus | HBV | NASH - Nonalcoholic Steatohepatitis | Human Immunodeficiency Virus | Chronic Liver Disease | HCV | Non-alcoholic Steatohepatitis | Hepatitis B Virus

United States, Spain, Taiwan, Italy, Belgium, France, Korea, Republic of, Canada, Russian Federation, Pakistan, Poland, India, Argentina
Fondazione Progetto Ematologia

Completed

Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)

Chronic Lymphocytic Leukemia | Purpura, Thrombocytopenic, Idiopathic | Non Hodgkin's Lymphoma | Autoimmune Thrombocytopenia | Autoimmune Thrombocytopenic Purpura

Italy
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy.

Chemotherapy-Induced Thrombocytopenia

China
Weill Medical College of Cornell University
Novartis

Completed

Safety and Efficacy of Eltrombopag at Escalated Doses

Immune Thrombocytopenia | Platelet Disorder

United States
Institute of Hematology & Blood Diseases Hospital

Recruiting

Hetrombopag for the Enhancement of Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation | Hematological Disease

China
University of Ulm
GlaxoSmithKline; WiSP Wissenschaftlicher Service Pharma GmbH; German CLL Study...

Terminated

Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG)

Thrombocytopenia | Chronic Lymphocytic Leukemia

Austria, Germany
Weill Medical College of Cornell University
Novartis

Terminated

End of EXTEND: Discontinuation of Medication for Patients With Immune Thrombocytopenia

Immune Thrombocytopenia

United States
Jiangsu HengRui Medicine Co., Ltd.

Withdrawn

A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia

Chemotherapy-Induced Thrombocytopenia
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia

Immune Thrombocytopenia

China
Institute of Hematology & Blood Diseases Hospital...
Xijing Hospital; Xi'an Central Hospital; The Second Hospital of Hebei Medical... and other collaborators

Active, not recruiting

A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts (TE-ITP)

Previously Treated Primary Immune Thrombocytopenia

China
Tel-Aviv Sourasky Medical Center
Novartis

Recruiting

Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART

B Cell Lymphoma | CART Treatment

Israel
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Eltrombopag in Second Line Adult Primary Immune Thrombosytopenia

Primacy Immune Thrombocytopenia

Italy
Novartis Pharmaceuticals

Completed

Drug Use Investigation for REVOLADE (ITP)

Purpura, Thrombocytopaenic, Idiopathic
Assiut University

Unknown

Eltrombopag in Chronic ITP

Immune Thrombocytopenia
Nanfang Hospital of Southern Medical University
Guangzhou First People's Hospital; Second Affiliated Hospital, Sun Yat-Sen... and other collaborators

Unknown

Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML

Acute Myeloid Leukemia | Thrombocytopenia | Eltrombopag

China
IRCCS Policlinico S. Matteo

Completed

Eltrombopag for Inherited Thrombocytopenias

Inherited Platelet Disorder

Italy
Dana-Farber Cancer Institute

Terminated

Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma

Multiple Myeloma | Thrombocytopenia

United States
GlaxoSmithKline

Completed

WEUSKOP5410: Observational Study in ENABLE Clinical Trials

Hepatitis C
GlaxoSmithKline

Completed

Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT)

Purpura, Thrombocytopaenic, Idiopathic

Germany, Russian Federation
French Innovative Leukemia Organisation
Novartis Pharmaceuticals

Active, not recruiting

Study Impact on Outcome of Eltrombopag in Elderly Patients With Acute Myeloid Leukemia Receiving Induction Chemotherapy (EPAG2015)

Acute Myeloid Leukemia

France
Novartis Pharmaceuticals

Completed

A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia

Cytopaenia

Japan
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Extension Study of Hetrombopag in Severe Aplastic Anemia

Treatment-naive Severe Aplastic Anemia

China
Technische Universität Dresden
Novartis

Terminated

A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML Patients (DELTA)

Acute Myeloid Leukemia

Germany
University Hospital, Lille

Recruiting

RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation (REGALIA)

Leukemia | Graft Failure

France
Novartis Pharmaceuticals

Terminated

Study of Efficacy and Safety of Eltrombopag in Patients With Poor Graft Function (ELTION)

Poor Graft Function

Spain
GlaxoSmithKline

Completed

Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment

Purpura, Thrombocytopaenic, Idiopathic

United States
GlaxoSmithKline

Completed

A Pharmacokinetic Study of Eltrombopag 50 Milligram (mg) in Healthy Volunteers Under Fasting Conditions

Cirrhosis, Liver

Mexico
University of Utah
Novartis

Completed

Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia

Severe Aplastic Anemia | Moderate Aplastic Anemia | Very Severe Aplastic Anemia

United States
Jane Liesveld

Completed

Phase I Study of Eltrombopag for Promoting Thrombopoiesis After Total Body Irradiation

Thrombocytopenia | Acute Radiation Syndrome
GlaxoSmithKline

Withdrawn

Milk-only Lactation Study for Patients on Eltrombopag

Thrombocytopaenia

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient

Idiopathic Thrombocytopenic Purpura

China
National Heart, Lung, and Blood Institute (NHLBI)

Completed

A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes | Thrombocytopenia

United States
M.D. Anderson Cancer Center
GlaxoSmithKline

Completed

Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)

Leukemia | CLL

United States
Groupe Francophone des Myelodysplasies
GlaxoSmithKline; Novartis

Completed

A Study of Eltrombopag in Patients With CMML and Thrombocytopenia

Thrombocytopenia | CMML

France
moshe yeshurun
GlaxoSmithKline

Unknown

Eltrombopag for Enhancing Platelet Engraftment in Pediatric Patients Undergoing Cord Blood Transplantation

Pediatric Patients Undergoing Allogeneic Cord Blood Transplantation.

Israel

Search clinical trials for: Placebo (for Eltrombopag)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations